Heparin TOP5 listed pharmaceutical companies Fawei, half a year a total of nearly 10 billion!

Recently, domestic listed pharmaceutical companies with heparin as the leading product have successively announced the performance of the first half of 2022, and the total half-year revenue of TOP5 enterprises is close to 10 billion yuan
.
At present, the domestic epidemic has entered the stage of normalization prevention and control, and the superimposed favorable policies have been gradually implemented, and the steady growth of revenue generation throughout the year has been a stable victory
.
According to analysts, the eighth batch of national procurement or will include enoxaparin sodium injection and nadroparin injection, price reduction is an inevitable trend, but the specific implementation time will be as soon as 2023 after the Spring Festival, the overall sales performance of the heparin industry in 2022 is still expected
.

 

The domestic heparin and low molecular weight heparin markets continue to rise

 

According to data from the Intranet, in the first half of 2022, the terminal market size of heparin and low-molecular weight heparin drugs in public hospitals in key provinces and cities in China exceeded 1.
180 billion yuan, an increase of 2.
59% year-on-year (see Figure 1).

 

　

 

According to the semi-annual report of the top five listed companies specializing in heparin products, in terms of revenue in the field of heparin products, Hepalink Pharmaceutical Group still ranks first, achieving revenue of 3.
759 billion yuan in the first half of the year, followed by Jianyou shares relying on the volume of preparation sales, and the operating performance has made progress, with revenue reaching 1.
975 billion yuan
.
Dongcheng Pharmaceutical ranked third with 1.
765 billion yuan; the fourth place was Changshan Pharmaceutical, with revenue of 1.
147 billion yuan in the first half of the year; and the fifth place was Qianhong Pharmaceutical, with a revenue of 1.
137 billion yuan
in the first half of the year.

 

The situation of the five major domestic heparin listed companies in the first half of 2022

Source: Semi-annual report of the company

 

Hepalink leads the revenue list

 

In the heparin enterprise revenue ranking, Hepalink still ranked first, achieving revenue of 3.
759 billion yuan in the first half of the year, an increase of 20.
72%
year-on-year.
The past three years have shown a sustained growth trend (see Figure 3
).
The company's net profit in the same period is also considerable, reaching 511 million yuan, a growth rate of 51.
15%.

Hepalink Pharmaceutical Group is a pharmaceutical company with an A+H dual financing platform, whose main business covers the investment, development and commercialization
of the whole industry chain of heparin, biomacromolecule CDMO and innovative drugs.
Its heparin product layout focuses on enoxaparin sodium and standard heparin, including APIs and their various specifications for injections
.

 

　　

 

Hepalink's Enoxaparin sodium injection was approved by the European Medicines Agency in 2016 through a centralized approval process; In October 2020, Hepalink and its subsidiary Shenzhen Tiandao Pharmaceutical's Enoxaparin sodium injection took the lead in passing the domestic generic drug quality and efficacy consistency evaluation, thus promoting the company's sales
in the domestic and foreign heparin preparation markets 。 According to the data of Intranet, in 2021, Shenzhen Tiandao Pharmaceutical has entered the first place in the domestic sodium market of domestic enoxaparin in public hospital terminals, and continued to grow steadily in the first half of 2022, and is in a leading position in the domestic enoxaparin sodium market, accounting for 27.
06% of the domestic enoxaparin sodium injection market in public hospitals (see Figure 2), an increase of 2.
23 percentage points
over 24.
83% in 2021.

 

 

According to Hepalink's semi-annual report, in the first half of 2022, the company's global sales of enoxaparin sodium preparations exceeded 114 million pieces, and the year-on-year sales volume in domestic sales terminals and overseas markets that have been opened up has achieved double-digit growth, of which the year-on-year sales growth in the US market has reached 184.
91%.

In recent years, the company has accelerated the investment in fixed assets, and three pre-filling filling production lines and four packaging lines of the 360 million / year preparation line of the Group's Pingshan Park have been officially launched
.

 

In addition, Hepalink has accelerated its pace in the field of innovative drug development, thereby increasing its competitiveness
.
In the first half of 2022, the company invested 82.
5163 million yuan in research and development, an increase of 19%
year-on-year.
Substantial progress
has been made in the research and development of new products such as Oregovomab, a targeted drug against advanced primary ovarian cancer, a fully human monoclonal IgG1 antibody AR-301 (Salvecin) against α toxins released by Staphylococcus aureus, and RVX-208 (Apabetalone) for acute coronary syndrome.

 

Jianyou shares net profit ranked first

 

According to the semi-annual report of Jianyou Shares, the company's revenue in the first half of 2022 was 1.
975 billion yuan, an increase of 12.
79%
year-on-year.
It is worth mentioning that the company's net profit was 614 million yuan, becoming a leader
in the five major heparin industries.

 

The company's business mainly covers cardiovascular, neurological, anesthetic, anti-tumor preparations, surgical aids and other drug varieties
.
In the heparin production line, there are three main varieties of enoxaparin sodium injection, nadroparin calcium injection and dar heparin sodium injection, and at the same time has the API supply chain
of the above products.
In April 2022, the company's enoxaparin sodium injection was included in the Chinese drug catalogue through consistency evaluation, and the consistency evaluation of natripteparin calcium injection and dalparin sodium injection has been reviewed and approved
.

 

According to the data of the Intranet, in the first half of 2022, Nanjing Jianyou in the domestic key provinces and cities of public hospital terminals, enoxaparin sodium injection, nadroparin calcium injection and heparin sodium injection market total sales, an increase of 38.
65% year-on-year (see Figure 4).

 

　

 

Since October 2019, Nanjing Jianyou acquired Meitheal Company in the United States, and overseas revenue growth will reach 50%
in 2021.
In 2020 and 2021, the high-end preparation pre-filling and sealing production line in Nanjing and the expansion project of injectable drug production line in Chengdu plant have ensured the supply chain of
domestic and foreign markets.

 

With the opening of the "U.
S.
-China Double Report" channel, the company's injection product line has been continuously enriched
.
Jianyou's enoxaparin injection has been approved in the European and South American markets, bringing multiple benefits
.
As of the end of the reporting period, the company held 64 drug production approvals in the United States, and has become one of the most complete suppliers of injection sales lines in the
United States.

 

In July 2022, the company's fondaparinus sodium injection, eteptidetide injection and tigecycline for injection successfully won the bid for the seventh batch of national procurement, providing experience
for the new round (eighth batch) of collective bidding and bidding.

 

Dongcheng and Changshan sales fluctuate, focusing on the layout

 

Dongcheng Pharmaceutical's core products are heparin sodium and chondroitin sulfate, with excellent quality, has won the certification of many international authoritative institutions, more than 90% of the products are sold to Europe, the Americas, Asia-Pacific and other countries and regions around the world, and many international well-known pharmaceutical companies have established long-term and stable cooperative relations
.

 

In the first half of 2022, the company achieved revenue of 1.
765 billion yuan, a slight decrease of 3%
year-on-year.
Due to the impact of the epidemic on the routine diagnosis and treatment business of the hospital, the company's preparations have been significantly affected, and the injection of nadroparin calcium has fallen by more than 30%
in public hospitals in key provinces and cities.
In the first half of 2022, the company's main income came from APIs, accounting for more than 60% of the company's total revenue; The total revenue of preparation products was 222 million yuan, an increase of 9.
66%
year-on-year.

 

Yantai Dongcheng North Pharmaceutical's application for the listing of enoxaparin injection, nadroparin injection and dar heparin injection has been reviewed and approved, and Dongcheng Pharmaceutical is in a poised future
.

 

Under the influence of the domestic epidemic in Changshan Pharmaceutical, the sales volume of the company's low molecular weight heparin calcium injection and heparin API in the first half of 2022 showed a downward trend, resulting in the company's operating income falling by 19.
11%
year-on-year.
According to the company's 2022 semi-annual report, the company's total revenue of heparin series preparations is 641 million yuan, and low molecular weight heparin calcium injection is the main variety, accounting for 62.
03%.

 

During the reporting period, the company increased investment in product transformation and consistency evaluation, and promoted the consistency evaluation process
.
In May 2022, Changshan Pharmaceutical was evaluated for nadroparin calcium injection, and then in July, enoxaparin sodium and daheparin sodium injection were evaluated, which is currently the manufacturer
of all three major domestic heparin evaluations.
The company is strengthening the academic transformation of the marketing team and preparing for the eighth batch of national procurement in advance
.

 

Intranet data, in the first half of 2022, the terminal of public hospitals in key provinces and cities, Changshan Pharmaceutical's low-molecular-weight heparin calcium injection fell by 13.
38%, while Enoxaparin sodium injection increased by 37.
07%, nadroparin calcium injection increased by 35.
33%, and heparin sodium injection increased by 17.
49%.

In order to increase the company's heparin API production capacity, the company launched an annual output of 35 tons of heparin series of API product projects, after the completion of the project can greatly improve the production capacity of APIs, promote the development of overseas markets, for the company's development plan in 2023 comprehensive layout
.

 

　

 

Qianhong Pharmaceutical's revenue and net profit both increased

 

According to the semi-annual report of Qianhong Pharmaceutical, the company's revenue in the first half of 2022 was 1.
137 billion yuan, an increase of 30.
23% year-on-year, and the net profit increased by 126.
42%.

The API series achieved operating income of 555 million yuan, an increase of 61.
87% year-on-year; The pharmaceutical series achieved operating income of 579 million yuan, an increase of 9.
44%
year-on-year.

 

During the reporting period, the company successfully obtained the consistency evaluation approval of enoxaparin sodium injection, and the on-site verification of the consistency evaluation of heparin sodium injection was completed, and the nadroparin calcium injection entered the consistency evaluation review, and obtained the new specification approval of the glass pre-filled needle heparin sodium sealing injection, which will become a new economic growth point for
the company's future development.

 

Choose the track and complement the growth

 

The main varieties of global low-molecular weight heparin injections are enoxaparin, daheparin and nadroparin, which are important biochemical drugs
for the prevention of intravenous and deep vein thrombosis and pulmonary embolism.
Domestic enoxaparin 7 reviews, nadroparin 4 reviews, heparin 1 review, low molecular weight heparin evaluation and national collection, indicating a new round of low molecular weight heparin variety purification and a new round of market reshuffle
.

 

On the track of heparin, Hepaline, Jianyou Shares, Changshan Pharmaceutical, Dongcheng Pharmaceutical, and Qianhong Pharmaceutical have formed a standing situation, but under the situation of rapid growth of antithrombotic small molecule chemicals, domestic fonda hepatide sodium has been approved, which has promoted market expansion
.
In addition, new oral anticoagulant drugs such as dabigatran ester, apixaban, rivaroxaban, and tegrelor continue to emerge, bringing new challenges
to low-molecular weight heparin injections.

 

Heparin enterprises in the cultivation of heparin business at the same time, the expansion of non-heparin business has become a consistent development needs, the above several companies have been in the choice of new tracks, more important than this is to expand overseas markets, to achieve multi-pattern complementary growth trend
.

 

Source: The company's semi-annual report, Intranet database Note: The chemical drug terminal competition pattern database of the key provinces and cities of the Intranet is based on the chemical drug procurement data of nearly 700 sample provinces and cities in 20+ provinces and cities, and continuously monitors the whole category of chemical drugs; The above sales are calculated
based on the average retail price of the product at the terminal.